Synopsis: Against the backdrop of a prolonged global agrochemical industry downcycle, PI Industries reported a 16% consolidated revenue decline in FY26 to Rs. 6,713.70 crore but held its EBITDA margin at 25% as guided, delivered a 507 basis point expansion in gross margins, and exited the year with Rs. 3,426.50 crore in surplus cash, even as its Pharma segment clocked 40% revenue growth with losses narrowing sharply.
Shares of a leading agrochemical contract manufacturer came into focus after filing its Q4 and FY26 results alongside an earnings presentation, with the numbers reflecting a company that managed margins carefully through a difficult export cycle while continuing to invest in its next growth platforms. The investor presentation was filed with BSE and NSE on19th May, 2026, ahead of an earnings call scheduled for 20th May.
With a market capitalisation of Rs. 44,074.11 crore, the shares of PI Industries Limited were last trading at Rs.2,903.5 per share, down 7.08 percent from its previous close of Rs.3.124.6. It is trading at a P/E of 36.05.
PI Industries reported consolidated revenue of Rs. 6,713.70 crore in FY26, a 16 percent decline from Rs. 7,977.80 crore in FY25. The drop was driven by two concurrent headwinds: agrochemical export revenue fell 19 percent year-on-year to Rs. 5,411.70 crore, as the global agchem industry continued its post-pandemic destocking cycle with export volumes down approximately 14 percent and pricing pressure accounting for the rest. Domestic agri business declined 7 percent to Rs. 1,302 crore, affected by adverse weather, lower crop prices, regulatory disruptions in Biologicals, and elevated channel inventories.
Despite the revenue decline, gross margins expanded 507 basis points to 58 percent a record for the company reflecting a favourable product mix as newer, proprietary molecules took a higher share of sales, and cost discipline across manufacturing. EBITDA came in at Rs. 1,705.30 crore, down 22 percent, with the margin at 25 percent precisely at the level management had guided for the year. Overheads grew 8 percent, primarily from investments in newer business development and new product promotion.
Net profit for FY26 stood at Rs. 1,320.80 crore, down 20 percent from Rs. 1,660.20 crore in FY25. This figure includes exceptional income of Rs. 126 crore from the writeback of contingent consideration, partially offset by a Rs. 22.90 crore Labour Code provisioning charge; stripping these out, underlying PAT was softer than the reported number suggests.
FY26 EPS stood at Rs. 87.1, against Rs. 109.4 in FY25. The board approved a final dividend of Rs. 10 per share, taking the total FY26 dividend to Rs. 15 per share, including the interim payout.
The March quarter continued to reflect the challenging environment. Revenue for Q4 FY26 was Rs. 1,565.20 crore, down 12 percent year-on-year, with export agchem declining 13 percent and domestic revenue falling 9 percent. EBITDA fell 26 percent to Rs. 337.30 crore, with margins compressing 402 basis points to 22 percent partly due to a higher share of non-SEZ business that lifted the effective tax rate in the quarter. Net profit declined 39 percent to Rs. 200.20 crore. Gross margins, however, improved 277 basis points year-on-year to 58 percent even in Q4, suggesting product mix continues to work in the company’s favour even as the topline remains under pressure.
Five new molecules were commercialised in exports during FY26, with new product revenue accounting for 18 percent of Agchem export revenue. Four products were launched in the domestic market. The active pipeline now stands at 90+ molecules, with over 60 percent in advanced development stages. Non-agchem enquiries spanning electronic and specialty chemicals have grown from about 15 percent of new enquiries in FY20 to over 40 percent in FY26, indicating a gradual diversification of the CSM customer base. The company holds 250+ patents, with 43 filed in FY26 alone.
In Biologicals, PI received US EPA registration for its Bionematocide during FY26, a significant regulatory milestone that enables commercial launches on the east of the Rockies. Global Biologicals revenue (ex-India) runs at an annualised rate of approximately USD 12 million with margins upward of 60 percent, and management expects double-digit growth to continue.
Pharma Business
PI Health Sciences, the company’s CRDMO arm, delivered 40 percent revenue growth in FY26 to Rs. 300.50 crore, though the business remains loss-making. Pre-tax loss narrowed 68 percent from Rs. 249.40 crore to Rs. 78.50 crore, the sharpest improvement since the division was set up. Revenue growth was driven by onboarding of new strategic and large pharma customers, and a shift toward integrated CRDMO services.
Q4 FY26 revenue was Rs. 104.80 crore, the highest quarterly sales for the Pharma segment with the pre-tax loss narrowing to Rs. 30 crore from Rs. 66.70 crore in Q4 FY25. Total Pharma enquiries nearly doubled year-on-year, and active customers grew from 77 to 86. Capex for the Pharma division stood at Rs. 91.70 crore in FY26, down from Rs. 127.50 crore, reflecting some moderation in build-out pace after capability investments in prior years.
Balance Sheet and Capex
PI Industries’ balance sheet remains one of the strongest in the Indian agrochemical space. The company is effectively debt-free, with surplus cash net of debt at Rs. 3,426.50 crore as of March 2026. Total capex for FY26 was Rs. 1,150.80 crore, up from Rs. 928 crore in FY25, as the company continued building manufacturing capacity across five sites. Three multipurpose plants are under construction.
Working capital held broadly stable quarter-on-quarter in Q4, though an increase over March 2025 levels reflects inventory buildup and selective credit extension in line with agchem market conditions. ROCE, computed excluding cash, declined to 18.8 percent from 28.9 percent in FY25 a cyclical compression that reflects lower profits against a higher capital base, not a structural deterioration.
Business Overview
PI Industries Limited, headquartered in Udaipur, Rajasthan, is among India’s leading agro-chemical companies, operating in contract synthesis and manufacturing for global innovators and in branded domestic agri-inputs. The company has progressively diversified into Pharma CRDMO through PI Health Sciences and into global Biologicals.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post PI Industries Shares Drop 7% on 16% FY26 Revenue Decline; Holds EBITDA Margin at 25% appeared first on Trade Brains.